|ADC Therapeutics SA, of Lausanne, Switzerland||Loncastuximab tesirine (ADCT-402)||CD19-targeted antibody-drug conjugate||Relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma||Dosed first patient in pivotal phase II portion of Lotis 3 phase I/II trial testing combination with Imbruvica (ibrutinib, Abbvie Inc.)|
|Aprea Therapeutics Inc., of Boston, a Karolinska Development AB portfolio company||Eprenetapopt||Reactivates mutant p53||Acute myeloid leukemia||Expanded enrollment in trial testing drug in TP53-mutant AML; following completion of safety lead-in portion, first expansion cohort will test combination of eprenetapopt with venetoclax and azacitidine in front-line disease; company also plans to activate cohort to test eprenetapopt with azacitidine in frontline TP53 mutant AML|
|Celltrion Group, of Incheon, Korea||Antiviral antibody||Antiviral antibody||COVID-19||Launched study aimed to enroll 32 healthy volunteers to test safety; completion of trial expected by third quarter of this year|
|Janssen Pharmaceutical Cos., of Raritan, N.J., part of Johnson & Johnson, and Meiragtx Holdings plc, of London||AAV-RPGR||AAV retinitis pigmentosa GTPase regulator||Inherited retinal disease X-linked retinitis pigmentosa||6-month data from ongoing phase I/II trial showed that low and intermediate doses were well-tolerated and indicated significant improvement in vision; significant differences in mean retinal sensitivity observed between treated and untreated eyes in intermediate dose cohort (1.02 decibel), and significant differences observed in central visual field progression rate (V30) between treated and untreated eyes|
|Phasebio Pharmaceuticals Inc., of Malvern, Pa.||PB-1046||Once-weekly, subcutaneous VIP receptor agonist||COVID-19||Dosed first patient in potentially pivotal Vangard trial, testing treatment in hospitalized patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome|
|China National Pharmaceutical Group Co. Ltd. (Sinopharm CNBG), of Beijing||Vaccine||Inactivated vaccine for COVID-19||COVID-19||First WHO-enlisted global trial started in Abu Dhabi|
|Eli Lilly and Co., of Indianapolis||Mirikizumab||Monoclonal antibody that binds to p19-subunit of IL-23||Moderate to severe plaque psoriasis||Met primary and all key secondary endpoints vs. placebo at week 16 (superiority) and all key endpoints vs. Cosentyx (secukinumab, Novartis AG) at week 16 (noninferiority) and week 52 (superiority) in Oasis-2 study|
For more information about individual companies and/or products, see Cortellis.